摘要
Abstract
Objective To conduct a systematic review of efficacy and safety of dabigatran 220 mg vs. enoxaparin for prevention of thromboembolism after hip or knee replacement. Methods CNKI, VIP, and Wanfang data Cochrane Library, Embase, Pubmed and Medline Databases, were searched from the 1990 to 2012. The references of these studies were also searched. Two independent researchers evaluated the included studies by using GRADE, the Meta-analysis was performed by Review Manager 5. 1 software. Results A total of 4 trials were reached the criteria, which included 10 265 patients. The efficacy of dabigatran 220 mg vs. enoxaparin has no significant difference for prevention of thromboembolism and the bleeding risk after hip or knee replacement, the results reveals that total VTE and all-cause mortality [ OR = 1. 01, 95% CI ( 0. 81 ~ 1.26)], proximal DVT [OR =0.76, 95% CI ( 0.55 ~ 1.07 )], major VTE and VTE related mortality [ OR =0.79,95% CI ( 0. 59 ~ 1. 06 ) ], major bleeding [ OR = 1. 11, 95% CI ( 0.75 ~ 1. 65 ) ], clinically relevant bleeding [ OR = 1. 18 , 95% CI ( 0. 92 ~ 1. 51 ) ]. Conclusion The efficacy of dabigatran 220 mg vs. enoxaparin has no significant difference for prevention of thromboembolism and the bleeding risk after hip or knee replacement.关键词
达比加群/依诺肝素/膝关节/髋关节/静脉血栓Key words
Dabigatran/ Enoxaparin/ Knee joint/ Hip joint/ Venous thromboembolism
